Dr. Eshleman's research program includes basic, translational, and clinical research. Her basic research program is focused on HIV diversity and its impact on HIV transmission, disease progression, and treatment outcomes. Her translational research program is focused on development and evaluation of assays and laboratory methods for HIV analysis. Dr. Eshleman directs two CAP-accredited laboratories at JHU: the HIV Genotyping Laboratory and the HIV Clinical Research Laboratory. Her clinical research program is focused on HIV prevention. She is also the Director of the HPTN Laboratory Center, one of three leadership groups of the NIH-sponsored HIV Prevention Trials Network (HPTN). This network performs cohort studies and clinical trials evaluating behavioral, biomedical, and structural interventions for HIV prevention in the US, Africa, South America, Asia, and Eastern Europe. Her research program and activities of the HPTN recently expanded to include research and clinical trials related to COVID-19.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto J, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielse-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, and Fleming TR. Antiretroviral treatment for prevention of HIV transmission: The final results of the HIV Prevention Trials Network (HPTN) 052 trial. NewEngJMed. 2016; 375:830-839.
Eshleman SH, Hudelson SE, Redd AD, Swanstrom R, Ou S-S, Zhang XC, Ping L-H, Piwowar-Manning E, Porcella SF, Sievers MF, Martens CA, Bruno D, Dukhovlinova E, McCauley M, Gamble T, Fogel JM, Sabin D, Quinn TC, Gunde L, Maliwichi M, NhandoN, Akelo V, Panchia R, Kumarasamy N, Chotirosniramit N, de Melo MG, Pilott J, Grinsztejn B, Mayer K, Chen YQ, Hughes JP, Cohen MS. Treatment as Prevention: Characterization of partner infections in the HIV Prevention Trials Network 052 trial. J AIDS. 2017; 74:112-116.
Coates TJ, Kulich M, Zelaya CE, Celantano DD, Chariyalertsak S, Chingono A, Gray G, Mbwambo JKK, Morin FS, Richter L, Sweat M, van Rooven H, McGrath N, Fiamma A, Laeyendecker O, Piwowar-Manning E, Szerekes G, Donnell D, and Eshleman SH. Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. Lancet Global Health.2014. 2:e267-e277.
Eshleman SH, Piwowar-Manning E, Wilson EA, Lennon D, Fogel JM, Agyei Y, Sullivan PA, Weng L, Moore A, Laeyendecker O, Kosloff B, Bwayla J, Maarman G, van Deventer A, Floyd S, Bock P, Ayles H, Fidler S, Hayes R, and Donnell D. Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART). Clinicaltrial: LaboratoryLead. J Int AIDS Soc. 2/2020; 23(2)e25452.
Zhang Y, Wymant C, Laeyendecker O, Grabowski MK, Hall M, Hudelson S, Piwowar-Manning E, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, Hakim JG, Kumwenda J, Mills LA, Santos BR, Grinsztejn, Pilotto JH, Chariyalertsak S, Makhema J, Chen YQ, Cohen MS, Fraser C, and Eshleman SH. Evaluation of phylogenetic analysis for inferring the direction of HIV transmission. Clin Infect Dis. 2020; ciz1247, https://doi.org/10.1093/cid/ciz1247.